National Institute on Drug Abuse (NIDA): all 393 studies

Page 4 of 4. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.

• Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7CompletedNCT00000358Phase 1
• Buprenorphine Maintenance for Opiate Dependence - 6CompletedNCT00000357Phase 2
• Evaluation of L-alpha-acetylmethadol (LAAM) in Methadone Patients - 5CompletedNCT00000356Phase 2
• Effects of Buprenorphine and Naloxone in Opiate Addicts - 4CompletedNCT00000355Phase 1
• Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3CompletedNCT00000354Phase 1
• Trial of Buprenorphine/Naloxone for Opiate Dependence - 2CompletedNCT00000353Phase 2
• Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1CompletedNCT00000352Phase 2
• Cognitive Correlates of Substance Abuse, Part 2 - 16Status unknownNCT00000351
• Effects of Stimulant Dependence on Human Striatal Dopamine System - 15Status unknownNCT00000350Phase 1
• Infusion Laboratory: Protocol 5 (Flupenthixol) - 14Status unknownNCT00000349Phase 1
• Infusion Laboratory: Protocol 4 (Dihydrexidine) - 13Status unknownNCT00000348Phase 1
• Risperidone for Treatment of Cocaine Dependence in Outpatients - 12CompletedNCT00000347Phase 2
• Cognitive Correlates of Substance Abuse - 11Status unknownNCT00000346Phase 4
• Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10CompletedNCT00000345Phase 1
• Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9CompletedNCT00000344Phase 2
• Brain Changes in Stimulant Dependent Subjects - 8CompletedNCT00000343Phase 4
• Risperidone for the Treatment of Cocaine Dependence - 7CompletedNCT00000342Phase 2
• Evaluation of Liquid vs. Tablet Buprenorphine - 6CompletedNCT00000341Phase 2
• Pemoline in the Treatment of Stimulant Dependence - 5WithdrawnNCT00000340Phase 2
• Infusion Laboratory: Protocol 3 (Risperidone) - 4Status unknownNCT00000339Phase 1
• Infusion Laboratory: Protocol 2 (Lisuride) - 3Status unknownNCT00000338Phase 1
• Infusion Laboratory: Protocol 1 - Selegeline - 2CompletedNCT00000337Phase 1
• Selegiline in Outpatient Treatment for Cocaine Dependence - 1CompletedNCT00000336Phase 2
• Activity Monitoring Assessment of Opiate Withdrawal - 4CompletedNCT00000335Phase 2
• Comparison of Buprenorphine and Methadone - 3CompletedNCT00000334Phase 2
• Evaluation of Benztropine for Cocaine Craving - 2CompletedNCT00000333Phase 2
• High Dose Nimodipine Treatment Adjunct - 1CompletedNCT00000332Phase 2
• Psychostimulant Abuse - Novel Treatment Approaches - 1CompletedNCT00000325Phase 1
• Tryptophan and Behavior Therapy for Cocaine Abuse - 1CompletedNCT00000324Phase 2
• Therapeutic Potential of Kappa-Opioids Against Cocaine - 1CompletedNCT00000323
• Tyrosine for Methamphetamine Dependence - 1CompletedNCT00000322Phase 2
• Methamphetamine Abuse Treatment in Patients With AIDS - 1CompletedNCT00000321Phase 4
• Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1CompletedNCT00000320Phase 1/2
• Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1CompletedNCT00000318Phase 2
• Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2CompletedNCT00000316Phase 1
• Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1CompletedNCT00000315Phase 1
• M-CPP and Fenfluramine in Cocaine Addicts - 3CompletedNCT00000314Phase 2
• Predictive Values of Serotonergic Alterations for Outcome - 2TerminatedNCT00000313Phase 1
• Alterations in Serotonergic Functions in Cocaine Addicts - 1CompletedNCT00000312Phase 1
• Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2TerminatedNCT00000310Phase 2
• Dextroamphetamine-Cocaine Behavioral Intervention - 5CompletedNCT00000308Phase 2
• Naltrexone as Adjunct in Alcoholic Cocaine Dependent Patients - 4CompletedNCT00000307Phase 2
• Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3CompletedNCT00000306Phase 2
• Dextroamphetamine as an Adjunct in Cocaine Treatment - 1CompletedNCT00000304Phase 2
• Study Comparing Liquid and Tablet Buprenorphine Formulations - 5CompletedNCT00000302Phase 3
• Buprenorphine Combination Tablet Feasibility - 1CompletedNCT00000298Phase 2
• Effects of Labetalol on Nicotine Administration in Humans - 14CompletedNCT00000297Phase 2
• Role of Metabolites in Nicotine Dependence (4) - 13CompletedNCT00000296Phase 2
• Progesterone Treatment in Female Smokers - 12CompletedNCT00000295Phase 2
• Effects of Carvedilol on Cocaine Use in Humans - 11CompletedNCT00000294Phase 2
• Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10CompletedNCT00000293Phase 3
• Acute Withdrawal From Smoked Cocaine - 9CompletedNCT00000292Phase 1
• Effects of Labetalol on Human Cocaine Use - 8CompletedNCT00000291Phase 2
• Stress Hormones and Human Cocaine Use - 7CompletedNCT00000290Phase 1
• Role of Metabolites in Nicotine Dependence (3) - 6CompletedNCT00000289Phase 2
• Role of Metabolites in Nicotine Dependence (2) - 5CompletedNCT00000288Phase 2
• Relapse Patterns in Female Cocaine Users - 4CompletedNCT00000287
• Effects of Nefazodone on Treatment of Female Cocaine Abusers - 3CompletedNCT00000286Phase 2
• Effects of Phenytoin on Cocaine Use in Humans - 2CompletedNCT00000285Phase 1
• Role of Metabolites in Nicotine Dependence (1) - 1CompletedNCT00000284Phase 2
• Cocaine Abuse and ADHD - 10CompletedNCT00000275Phase 2
• Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9CompletedNCT00000274Phase 2
• Pergolide Treatment for Substance Abusers - 4CompletedNCT00000269Phase 2
• Cocaine Abuse and Attention Deficit Disorder - 3CompletedNCT00000268Not applicable
• Risperidone Treatment in Dually-Diagnosed Individuals - 2CompletedNCT00000267Phase 2
• Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1CompletedNCT00000266Phase 2
• Evaluation of a Desipramine Ceiling in Cocaine Abuse - 1CompletedNCT00000245Phase 2
• Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on MethadoneTerminatedNCT00000243Not applicable
• Flupenthixol Decanoate in Methamphetamine Smoking - 1CompletedNCT00000241Phase 2
• Buprenorphine Pharmacology Related to Addiction Treatment - 21CompletedNCT00000239Phase 2
• Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20CompletedNCT00000238Phase 2
• Buprenorphine Detoxification - BBDVI - 19CompletedNCT00000237Phase 2
• Buprenorphine Pharmacology Related to Addiction Treatment - 18CompletedNCT00000236Phase 2
• Alternate Day Buprenorphine Administration, Phase XII - 17CompletedNCT00000235Phase 2
• Alternate Day Buprenorphine Administration, Phase X - 15CompletedNCT00000233Phase 2
• Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13CompletedNCT00000231Phase 2
• Buprenorphine Detox With Two Types of Treatment. BBD I - 10CompletedNCT00000228Phase 2
• Alternate-Day Buprenorphine Administration. Phase VII - 8CompletedNCT00000226Phase 2
• Alternate-Day Buprenorphine Administration. Phase VI - 7CompletedNCT00000225Phase 2
• Alternate-Day Buprenorphine. Phase V - 6CompletedNCT00000224Phase 1
• Alternate-Day Buprenorphine Administration. Phase IV - 5CompletedNCT00000223Phase 2
• Alternate-Day Buprenorphine Administration. Phase II - 4CompletedNCT00000222Phase 1
• Alternate-Day Buprenorphine Administration. Phase I - 3CompletedNCT00000221Phase 1
• Gradual Vs. Rapid Buprenorphine Detoxification - 2CompletedNCT00000220Phase 1
• Pharmacotherapy and Intensive Treatment - 2CompletedNCT00000218Phase 4
• IV Cocaine Abuse: A Laboratory Model - 4CompletedNCT00000215Phase 2
• Treatment Efficacy for Drug Abuse and AIDS Prevention - 2CompletedNCT00000211Phase 2
• Treatment Efficacy for Drug Abuse and AIDS Prevention - 1CompletedNCT00000210Phase 2
• Buprenorphine Dosing Interval - 5CompletedNCT00000209Phase 2
• Methadone/Buprenorphine Cross-Over Study - 4CompletedNCT00000208Phase 2
• Pharmacological Modulation of Cocaine Effects - 1CompletedNCT00000201Phase 2
• Cocaine Effects in Humans: Physiology and Behavior - 1CompletedNCT00000200Phase 2
• Propranolol for Treatment of Cocaine Addiction - 2CompletedNCT00000197Phase 2

← National Institute on Drug Abuse (NIDA) overview and focus areas